Introduction
deteriorating renal function with nephrotic syndrome, requiring preparation for renal replacement therapy. Sotalol and digoxin were continued. Progressive renal failure can result in toxic plasma During hospitalization episodes of syncope lasting concentrations of drugs with primarily renal clearance. 10-20 s were observed, not due to hypoglycaemia. A Sotalol, a b-blocking agent with class III ( lengthening transthoracic echocardiogram, made to exclude cardiac refractory period and QT time) antiarrhythmic properemboli, showed short bouts of ventricular tachycardia ties, is largely excreted unchanged in the urine. It is without substantial cardiac output. During these indicated for supraventricular and ventricular tachyperiods the patient had syncope again. An ECG was cardia and prescribed with increasing frequency. QT made and is shown in Figure 1 . K+ was 3.9, Ca2+ prolongation is associated with torsade de pointes, a 2.09 mmol/l and Mg2+ 0.87 mmol/l. Sotalol-induced potentially lethal form of polymorphic ventricular torsade de pointes starting in periods of slow sinus tachycardia. We describe a patient with chronic sotalol rhythm (55 beats per minute) in a patient with endtherapy and progressive renal failure who developed stage renal failure was diagnosed. Two periods of torsade de pointes, successfully treated with haemodiaventricular fibrillation required defibrillation. Sotalol lysis and temporary transvenous electrical pacing.
and digoxin were discontinued. The digoxin concentration later proved to be under the therapeutic range (0.5 nmol/l ).
Case report
We inserted a temporary ventricular pacemaker set at a minimum rate of 90 beats per minute to decrease A 47-year-old Asian man presented with hypoglycaethe risk of bradycardia-induced recurrence of torsade mia. For the past 17 years he had been known to have de pointes. After haemodynamic stabilization haemohypertension and non-insulin-dependent diabetes meldialysis was started to achieve enhanced sotalol elimlitus, which were complicated by retinopathy and slow ination. Because of his long-standing uraemic situation deterioration of renal function. Two years before dialysis was limited to 3 h to prevent the occurrence admission he had an episode of left-sided heart failure of convulsions; blood flow 200 ml/min; dialysate due to paroxysmal atrial flutter, treated with electrical bicarbonate Gambro N-252-S ( K+ 3.0 mmol/l with cardioversion, propafenone, and later sotalol. His medglucose), flow 500 ml/min, conductivity 14.0 cm/s2, ication on presentation included enalapril 20 mg, sotaultrafiltration 100 ml/h for 3 h using Gambro F6 lol 80 mg t.i.d., digoxin 0.125 mg, insulin, bumetanide artificial kidney. A second haemodialysis treatment 3 mg b.i.d., and allopurinol. Laboratory results were followed 16 h later. Heart rate and QT-time were as follows: glucose 1.4 mmol/l, Hb 8.5 g/dl, potassium monitored constantly and blood samples were fre-5.2 mmol/l, creatinine 870 mmol/l, BUN 24.1 mmol/l, quently drawn. albumin 21 g/l.
After start of haemodialysis QT c time shortened in The endogenous creatinine clearance according to concert with sotalol concentrations. The patient still Cockroft and Gault [1 ] was 9.4 ml/min. An electrocarhad sporadic non-sustained ventricular tachycardia for 5 days, but no further episodes of torsade de pointes S. H. M. van Uum et al. 332 Sotalol concentrations were determined using an normalized to 0.5 s, the maximal recommended QT c time during sotalol therapy [9] . At that time the plasma high-performance liquid chromatography assay. Plasma sotalol concentrations are shown in Figure 2 . sotalol concentration was 3.3 mg/ml. Without haemodialysis it was calculated to be 110 h before the plasma Haemodialysis effectively reduced sotalol concentrations. The half-life of sotalol during haemodialysis was sotalol concentration would have declined to this level.
Thus, haemodialysis shortened the period at risk of 4.5 h, thereafter the half-life without haemodialysis was 96 h.
torsade de pointes by 73 h. Considering the increasing use of sotalol, it is important to emphasize that in a patient with increasing renal Discussion failure sotalol dose should be adjusted to creatinine clearance, QT c times should be monitored closely, and Sotalol is a racemic mixture of (+)sotalol and that haemodialysis can be used to shorten the period (−)sotalol, the (−)sotalol has class II (b-blocking) at risk of sotalol-induced life threatening episodes of activity. Both enantiomers have class III antiarrhyth-torsade de pointes. mic properties with inherent risk for torsade de pointes.
The incidence of torsade de pointes increases with 
